Doctors track new Virus-Fighting drugs in vulnerable transplant patients
NCT ID NCT04690933
Summary
This study observed 400 adult patients who received a stem cell transplant to see how well different anti-CMV drugs worked in real-world hospital settings. The goal was to track how often the drugs prevented or treated CMV infections, if the virus became resistant to the medications, and what side effects occurred. Researchers gathered this information to help improve future care for these high-risk patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP
Paris, France
-
CHU
Amiens, France
-
CHU
Angers, France
-
CHU
Besançon, France
-
CHU
Bordeaux, France
-
CHU
Caen, France
-
CHU
Clermont-Ferrand, France
-
CHU
Grenoble, France
-
CHU
Montpellier, France
-
CHU
Nancy, France
-
CHU
Poitiers, France
-
CHU
Rouen, France
-
CHU
Saint-Etienne, France
-
CHU
Strasbourg, France
-
CHU de LIMOGES
Limoges, Limoges, 87045, France
-
HCL
Lyon, France
Conditions
Explore the condition pages connected to this study.